Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low - Barron's

Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low - Barron's
Business

Listen to this article

0%

Sionna Therapeuticsis shelving its highly anticipated cystic fibrosis drug candidate, SION-719, after it failed to meet the key endpoint in a proof-of-concept trial. Copyright Β©2026Dow Jones & C… [+65 chars]

Leave A Comment

Comments are moderated and may take time to appear.

Comments

No comments yet. Be the first to comment!

Stay Connected